Shanghai Hile Bio-Technology Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Shanghai Hile Bio-Technology Co., Ltd. carries a market capitalization of 1.92B, placing it among publicly traded companies globally. Its enterprise value stands at 3.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.92B |
| Enterprise Value | 3.72B |
Share Statistics
Shanghai Hile Bio-Technology Co., Ltd. currently has 655.66M shares outstanding.
| Shares Outstanding | 655.66M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Shanghai Hile Bio-Technology Co., Ltd. trades at a trailing price-to-earnings ratio of 23.27. The price-to-sales ratio is 14.84, and the price-to-book ratio stands at 3.30.
| PE Ratio | 23.27 |
| PS Ratio | 14.84 |
| PB Ratio | 3.30 |
| P/TBV Ratio | 6.07 |
| P/FCF Ratio | 461.56 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Shanghai Hile Bio-Technology Co., Ltd. trades at an EV/EBITDA multiple of 45.45 and an EV/FCF ratio of 327.30. The EV/Sales ratio of 13.60 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 45.45 provides insight into valuation relative to core operating earnings.
| EV / Sales | 13.60 |
| EV / EBITDA | 45.45 |
| EV / EBIT | 45.45 |
| EV / FCF | 327.30 |
Financial Position
Shanghai Hile Bio-Technology Co., Ltd. maintains a current ratio of 8.62, meaning it holds 8.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.90, indicating moderate leverage, while an interest coverage ratio of 28.38 demonstrates strong ability to service its debt obligations.
| Current Ratio | 8.62 |
| Quick Ratio | 6.44 |
| Debt / Equity | 0.90 |
| Debt / EBITDA | 0.19 |
| Interest Coverage | 28.38 |
Financial Efficiency
Shanghai Hile Bio-Technology Co., Ltd. posts a return on equity of 15.78 and a return on invested capital of 4.82.
| Return on Equity (ROE) | 15.78 |
| Return on Assets (ROA) | 10.11 |
| Return on Invested Capital (ROIC) | 4.82 |
| Return on Capital Employed (ROCE) | 12.33 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.93 |
Taxes
Over the trailing twelve months, Shanghai Hile Bio-Technology Co., Ltd. has paid 24.99M in income taxes, reflecting an effective tax rate of 10.95.
| Income Tax | 24.99M |
| Effective Tax Rate | 10.95 |
Stock Price Statistics
Shanghai Hile Bio-Technology Co., Ltd.'s stock has declined approximately -61.26482% over the past 52 weeks. The 50-day moving average sits at 3.40, while the 200-day moving average is 5.31.
| Beta (5Y) | N/A |
| 52-Week Price Change | -61.26482% |
| 50-Day Moving Average | 3.40 |
| 200-Day Moving Average | 5.31 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shanghai Hile Bio-Technology Co., Ltd. generated 273.22M in revenue and converted that into 174.29M in net income, yielding earnings per share of 0.37. EBITDA reached 81.75M, while operating income came in at 81.75M.
| Revenue | 273.22M |
| Gross Profit | 196.42M |
| Operating Income | 81.75M |
| Pretax Income | 228.23M |
| Net Income | 174.29M |
| EBITDA | 81.75M |
| EBIT | 81.75M |
| Earnings Per Share (EPS) | 0.37 |
Balance Sheet
Shanghai Hile Bio-Technology Co., Ltd. holds 515.82M in cash and equivalents against 15.62M in total debt, resulting in a net debt position of -353.23M. Total book value stands at 1.23B, with working capital of 610.82M providing operational flexibility.
| Cash & Cash Equivalents | 515.82M |
| Total Debt | 15.62M |
| Net Debt | -353.23M |
| Equity (Book Value) | 1.23B |
| Book Value Per Share | 2.25 |
| Working Capital | 610.82M |
Cash Flow
After subtracting -8.79M in capital expenditures, free cash flow totaled -8.79M - equivalent to -0.02 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -8.79M |
| Free Cash Flow | -8.79M |
| FCF Per Share | -0.02 |
Margins
Shanghai Hile Bio-Technology Co., Ltd. operates with a gross margin of 71.89, reflecting its pricing power and cost economics. The operating margin of 29.92 and net profit margin of 63.79 provide insight into operational efficiency.
| Gross Margin | 71.89 |
| Operating Margin | 29.92 |
| Pretax Margin | 83.53 |
| Profit Margin | 63.79 |
| EBITDA Margin | 29.92 |
Dividends & Yields
The company's payout ratio of 8.91 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.04 |
| Dividend Yield | N/A |
| Payout Ratio | 8.91 |
| Shareholder Yield | -3.77 |
| FCF Yield | 0.22 |
Stock Splits
Shanghai Hile Bio-Technology Co., Ltd.'s most recent stock split took place on May 5, 2016 with a 10:23 split ratio.
| Last Split Date | 5/5/2016 |
| Split Ratio | 10:23 |
Scores
Shanghai Hile Bio-Technology Co., Ltd. posts an Altman Z-Score of 26.65, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 26.65 |